PLRX | Pliant Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	12.57 - 13.64
52 Week Range	10.29 - 19.62
Beta	0.75
Implied Volatility	62.40%
IV Rank	38.60%
Day's Volume	177,953
Average Volume	542,779
Shares Outstanding	60,801,400
Market Cap	782,514,018
Sector	Healthcare
Industry	Biotechnology
IPO Date	2020-06-03

Valuation
Profitability
Growth
Health
P/E Ratio	-4.17
Forward P/E Ratio	N/A
EPS	-3.09
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	158
Country	USA
Website	PLRX

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

PLRX's peers: ACET, ADAP, ADMA, AGIO, ARCT, ARVN, ASND, CABA, CALT, CYTK, DTIL, DYN, ERAS, ETNB, GALT, HRMY, IMVT, LEGN, MDGL, MORF, MRSN, NRIX, RLAY, STOK, BDTX, ACLX, RVMD, SNDX, VRDN, INZY, TCRR, BCEL, PASG, PRTA, PSTX, PTGX, RAPT, RCKT, RGNX, RNA, ROIV, RVNC, RYTM, SAGE, SRRK, SWTX, TNGX, TSVT, VCEL, VRCA, MLTX, PROK

*Chart delayed

Analyzing fundamentals for PLRX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is passable. For more detailed analysis please see PLRX Fundamentals page.

Watching at PLRX technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, but short-term trend is bullish. More technicals details can be found on PLRX Technicals page.